Sunrise

Sunrise operates in health diagnostics and medical devices, with a focus on at-home sleep apnea testing and a virtual-clinic model. Its stated point of differentiation is measuring mandibular movements with a small chin sensor, rather than relying on a conventional setup that requires multiple sensors or an overnight laboratory visit. The company describes its diagnostic performance as comparable to established in-lab sleep studies, and its product information cites clinical research and NICE guidance. Sunrise Air’s 2026 FDA clearance adds a rechargeable, multi-night option to its product direction. In comparison with in-lab polysomnography, the value proposition is greater convenience and home use; that benchmark remains distinct from a direct competitor. Sunrise’s challenge is to demonstrate that accessibility and its mandibular-movement approach translate into clinical confidence, adoption by healthcare professionals, and effective follow-up. Its virtual-clinic services and sleep-specialist pathway broaden the offering beyond the sensor itself, while its Belgian base and U.S. advisory appointments indicate ambitions across healthcare markets.

Sunrise was founded in 2015 and has developed from a sleep-diagnostics device company into a broader virtual-clinic offering that includes an at-home test, a patient and clinician platform, and specialist follow-up. Its funding history includes a €1 million pre-seed round in 2019, a €6.5 million seed round in 2021, and a €17 million Series A in March 2023. A separate $6 million investment is listed for November 2023, while a €25 million venture round followed on Sep 25, 2025, led by Eurazeo. The 2025 financing and the 2026 FDA clearance for rechargeable Sunrise Air mark notable inflection points in capital and product development. In May 2026, the company established a U.S. Medical Advisory Board with Dr. Atul Malhotra and Dr. Diana Thiara, signaling an effort to strengthen clinical guidance as it develops its U.S. presence. Funding totals and round records contain inconsistencies, so the precise relationship between reported financing and cumulative capital remains uncertain.